Genetesis

13 articles about Genetesis

• Genetesis Announces Formal Publication of Results from the MAGNETO Trial

  4/2/2024

  Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice.

• Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG

  4/13/2023

  Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD).

• Genetesis Announces New Appointments to Executive Leadership Team

  1/20/2023

  Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux.

• Genetesis Announces Close of $17.5 Million Series C Financing

  10/6/2022

  Genetesis, the market leader in next-generation biomagnetic imaging, has announced that it has closed $17.5 million in Series C Financing.

• FDA Awards Genetesis Breakthrough Device Designation for CardioFlux® Imaging Technology

  12/15/2020

  Genetesis, Inc. announced today that its flagship product, CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome. CardioFlux®, the most advanced commercially available magnetocardiograph (MCG), leverages highly sensitive room temperature magnetomet

• Cardiac Imaging Company Genetesis Adds TDK Ventures as Strategic Investor and Welcomes New Board Member

  5/7/2020

  Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFlux™ imaging, today announced several important updates.

• Peter Donato Joins Genetesis as Chief Business Officer

  8/26/2019

  Genetesis Inc., a medical device and digital health company developing technologies for detection of heart disease, today announced that it expanded its executive leadership team by adding Peter Donato, seasoned public company and IPO/pre-IPO executive, as its Chief Business Officer.

• Genetesis CardioFlux™ Platform Receives FDA 510(k) Clearance

  3/22/2019

  Next-generation magnetocardiography and cloud computing enable rapid, non-invasive cardiac imaging in the Emergency Department

• Biomagnetic Imaging Company Genetesis Closes $7.5M in Series A Financing

  6/5/2018

  Patient Study Advances Development of New Tool to Assist Clinicians in Triage of Chest Pain

• Mike Hooven, Founder Of AtriCure And Enable Injections, Joins Genetesis Board Of Directors

  10/11/2017

• Meet the 21-Year-Old College Student Who's Running Biotech Startup Genetesis

  12/13/2016

• Medtech Startup Genetesis to Map Cardiac Disorders Backed by Mark Cuban

  11/18/2016

• Cardiac Imaging Company Genetesis Closes $1.2 Million In Seed Financing

  11/14/2016